Clozapine (Clozaril): Uses, Dosing, Side Effects, REMS/ANC Monitoring & Safety Guide

Baseline ANC before starting:

• General population≥ 1500/µL
• BEN (Duffy‑null) patients≥ 1000/µL (obtain at least two baseline ANCs)

Ongoing ANC frequency (typical U.S. schedule):

• Weeks 0–26 (first 6 months)weekly
• Weeks 27–52 (months 6–12)every 2 weeks
• After 12 months of continuous therapymonthly (ongoing)

Common (many improve as you adjust):

Drowsiness/sedation, weight gain & metabolic changes, fast heartbeat, hypersalivation, dizziness (esp. when standing), constipation, nausea. Track bowel habits, hydration, and physical activity; ask about prevention strategies from day one.

Serious. Call your prescriber urgently or seek emergency care:

• Fever, sore throat, signs of infection (could signal low neutrophils).

• Severe constipation or abdominal pain, bloating, vomiting (GI hypomotility/ileus can be life‑threatening).

• Chest pain, shortness of breath, palpitations (possible myocarditis/cardiomyopathy), especially in first ~4 weeks.

• Fainting, severe dizziness, seizures.

Neutropenia/Agranulocytosis

The reason for ANC checks: rare severe neutropenia can occur; structured monitoring reduces risk. Follow your lab schedule precisely and report infections promptly.

Myocarditis & cardiomyopathy

Risk is greatest in the first month. Many services monitor CRP and troponin weekly alongside the CBC for 4 weeks to catch early signals; discuss with your prescriber what labs are planned. Watch for chest pain, breathlessness, fast heartbeat, fever, or fatigue.

Gastrointestinal hypomotility (constipation)

Clozapine can slow the gut and lead to severe constipation or even ileus. Start preventive measures early (hydration, fiber, activity, stool plan if needed) and report any red‑flag symptoms.

Pregnancy & breastfeeding

Data are limited and decisions are individualized, balancing relapse risk and maternal/fetal safety. If you’re pregnant, planning pregnancy, or breastfeeding, consult your prescriber early to plan monitoring and dosing; do not stop clozapine abruptly. (See label and major clinical resources for current cautions.)

Therapeutic Drug Monitoring (TDM): When do blood levels help?

Many services check plasma levels if response is partial, side effects emerge, smoking status changes, or adherence is uncertain. A frequently cited response threshold is ≥ ~350 ng/mL, with a commonly referenced range of ~350–600 ng/mL (clinical context matters). Your clinician will interpret levels with symptoms and side effects, not numbers alone.

Discontinuation, withdrawal, and re‑starting

Avoid abrupt discontinuation unless medically necessary. Rapid cessation can trigger rebound psychosis and cholinergic rebound (nausea, vomiting, diarrhea, sweating, insomnia, agitation), and rarely catatonia or serotonin syndrome. Planned tapers (often 1–2 weeks minimum; slower is common) reduce risk. If restarted after a gap (≥48 hours), clinicians typically re‑titrate from a low dose.